4 Result(s)

Article

Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer

Ari Nishimura, Akira Ono, Kazushige Wakuda, Takanori Kawabata… in Investigational New Drugs (2022)

Article

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

Background. Prognostic data on Japanese patients receiving durvalumab after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are insufficient. Whether pneumonitis has prognostic ...

Ari Nishimura, Akira Ono, Kazushige Wakuda, Takanori Kawabata… in Investigational New Drugs (2022)

Article

Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Corrections are needed to the original version of this article. In Table 2, the “Odds ratio” of the variables “Lower lobe vs. Upper lobe” and “≥26 vs. <26” should be 2.250 instead of 2250 and 2.250 instead of ...

Hiroto Inoue, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya… in Investigational New Drugs (2021)

Article

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Introduction Durvalumab has been shown to confer a survival benefit after definitive chemoradiotherapy in the patients with locally advanced non-small cell lung cancer, but no studies have attempted to identify r...

Hiroto Inoue, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya… in Investigational New Drugs (2020)